Movatterモバイル変換


[0]ホーム

URL:


Journal Logo

Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.

Export to

Proceedings Of The Fifth International Congress Of Therapeutic Drug Monitoring And Clinical Toxicology

Use and Abuse of the Benzodiazepines

Fraser, Albert D.

Author Information

Department of Pathology and Laboratory Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada

Received February 11, 1998; accepted April 16, 1998.

Address correspondence and reprint requests to Albert D. Fraser, Department of Pathology and Laboratory Medicine, Queen Elizabeth II Health Sciences Centre, 1278 Tower Road, Halifax, Nova Scotia, Canada B3H 2Y9.

Therapeutic Drug Monitoring20(5):p 481-489, October 1998.

Abstract

Since chlordiazepoxide was introduced in 1961, the benzodiazepines have had many important roles in the pharmacotherapy of various disorders. This drug class for the central nervous system has been considered one of the safest in use for 35 years, especially when the benzodiazepines are compared with the barbiturates they often replaced. The objective of this article is to provide an update on the availability and distribution of benzodiazepines around the world and to discuss their most common clinical applications. Adverse effects of benzodiazepines, observed after long-term therapeutic use and after overdoses, are also presented. Triazolam is discussed because this benzodiazepine was removed from the market by regulatory authorities in the United Kingdom in 1991. Benzodiazepines will continue to have an important role in clinical medicine. Their clinical use, however, should be monitored more closely because of the greater awareness of their adverse effects after long-term use and because of the potential for misuse and abuse.

© 1998 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Log InAccess through Ovid

Source

Therapeutic Drug Monitoring20(5):481-489, October 1998.
Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.


[8]ページ先頭

©2009-2026 Movatter.jp